Equities

Benson Hill Inc

BHIL:NYQ

Benson Hill Inc

Actions
Consumer Staples Food Producers
  • Price (USD)0.2196
  • Today's Change0.000 / -0.18%
  • Shares traded625.61k
  • 1 Year change-81.70%
  • Beta--
Data delayed at least 15 minutes, as of May 06 2024 18:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Benson Hill, Inc. is an ag-tech company. The Company offers CropOS, which is a product design and development platform that uses predictive breeding and other advanced tools like CRISPR gene editing technology. The Company is engaged in the sale of soybean grain, soybean oil, soybean meal, soybean flakes and soybean flour and texturized flour, sales of processed yellow peas and sales of seed, as well as technology licensing fees and royalties. Its CropOS platform aggregates proprietary protein, genomic, and strategic data layers for predictive breeding using artificial intelligence (AI) and machine learning (ML) and its Crop Accelerator, an indoor year-round speed breeding and rapid prototyping facility. It is developing a diversified seed portfolio spanning the key markets, such as protein ingredients, aquaculture and specialty animal feed, and vegetable oils. The Company sells its products throughout North America, in Europe and in several countries globally.

  • Revenue in USD (TTM)473.34m
  • Net income in USD-111.25m
  • Incorporated2020
  • Employees270.00
  • Location
    Benson Hill Inc1001 N. Warson Rd., Ste 300ST. LOUIS 63132United StatesUSA
  • Phone+1 (314) 222-8218
  • Fax+1 (302) 655-5049
  • Websitehttps://bensonhill.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cyclo Therapeutics Inc1.08m-20.06m43.36m8.00--9.06--40.28-1.33-1.330.06790.16660.12330.38712.14134,551.30-229.72-132.22-727.50-215.1790.8590.37-1,863.35-1,114.041.42-2,769.340.00---21.761.25-29.81---3.95--
Xilio Therapeutics Inc0.00-76.40m43.56m73.00--0.8846-----2.78-2.780.001.330.00----0.00-76.37---93.74-------------131.890.0826------13.40------
Matinas BioPharma Holdings Inc1.10m-22.94m43.87m32.00--1.97--40.03-0.1056-0.10560.0050.08860.0314----34,250.00-65.62-44.62-72.81-48.25-----2,093.25-2,344.60----0.0012---65.6255.71-9.26---16.46--
IN8BIO, Inc.0.00-30.01m44.02m31.00--1.74-----1.02-1.020.000.57610.00----0.00-89.91-74.18-108.07-84.42------------0.0466-------5.21---4.54--
Sensei Biotherapeutics Inc0.00-34.10m44.88m27.00--0.6904-----1.21-1.210.002.590.00----0.00-35.38-47.03-38.31-54.33------------0.0247------29.82--42.16--
Movano Inc0.00-29.28m46.17m30.00--7.61-----0.6463-0.64630.000.06180.00----0.00-258.41-151.50-496.87-188.58--------1.26--0.014------3.45--4.24--
Rockwell Medical Inc80.83m-9.29m46.40m253.00--2.09--0.574-0.5462-0.54624.260.75531.5113.839.66319,494.10-17.40-53.82-28.13-73.1010.111.75-11.49-46.171.06-6.740.3517--17.574.9142.83---30.09--
Benson Hill Inc473.34m-111.25m46.64m270.00--0.5328--0.0985-0.5914-0.61312.520.41291.2210.2714.811,753,096.00-28.68---38.28--4.993.18-23.50-40.730.9166-2.330.4509--24.16156.43-11.58--63.78--
Arca Biopharma Inc0.00-6.00m47.29m4.00--1.35-----0.4155-0.41550.002.420.00----0.00-15.24-27.78-15.81-29.38------------0.00------46.21------
Medicine Man Technologies Inc172.45m-42.70m48.52m729.00--0.3845--0.2814-1.60-1.603.011.610.50643.9939.49236,553.90-10.15-8.33-11.95-9.8544.0845.57-20.03-15.710.50270.31430.5679--8.2078.78-62.56--200.89--
Immuneering Corp0.00-53.47m48.63m68.00--0.530-----1.89-1.890.003.090.00----0.00-47.54---51.16--------------0.00---100.00---5.86------
Ocuphire Pharma Inc19.05m-9.99m49.38m14.00--0.9561--2.59-0.4735-0.47350.87272.080.3701--5.301,360,643.00-19.40-58.31-20.77-65.94-----52.42-137.92---8.460.00---52.20---155.83------
Modular Medical Inc0.00-16.76m49.89m37.00--8.92-----0.9653-0.96530.000.18050.00----0.00-224.40-168.16-262.22-209.51------------0.00------25.51--154.53--
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Correlate Energy Corp7.56m-12.79m50.15m19.00------6.63-0.3554-0.35540.21-0.08772.22--13.19398,051.60-375.16-315.47----18.2715.42-169.09-201.03---0.72398.30--122.2046.12-78.54------
Data as of May 06 2024. Currency figures normalised to Benson Hill Inc's reporting currency: US Dollar USD

Institutional shareholders

24.33%Per cent of shares held by top holders
HolderShares% Held
Builders Vision LLCas of 31 Dec 202311.49m5.52%
BlackRock Fund Advisorsas of 31 Dec 202310.47m5.02%
The Vanguard Group, Inc.as of 31 Dec 20238.09m3.88%
The Caisse de d�p�t et placement du Qu�becas of 31 Dec 20235.10m2.45%
BlackRock Financial Management, Inc.as of 31 Dec 20234.51m2.16%
Geode Capital Management LLCas of 31 Dec 20233.00m1.44%
SSgA Funds Management, Inc.as of 31 Dec 20232.98m1.43%
Fortem Financial Group LLCas of 31 Mar 20242.95m1.41%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 20231.15m0.55%
Cohen & Steers Capital Management, Inc.as of 31 Dec 2023962.50k0.46%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.